Morepen Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Morepen Laboratories has a total shareholder equity of ₹11.1B and total debt of ₹334.9M, which brings its debt-to-equity ratio to 3%. Its total assets and total liabilities are ₹15.6B and ₹4.5B respectively. Morepen Laboratories's EBIT is ₹1.8B making its interest coverage ratio 65.5. It has cash and short-term investments of ₹1.9B.
Key information
3.0%
Debt to equity ratio
₹334.95m
Debt
| Interest coverage ratio | 65.5x |
| Cash | ₹1.86b |
| Equity | ₹11.10b |
| Total liabilities | ₹4.52b |
| Total assets | ₹15.62b |
Recent financial health updates
Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Recent updates
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump
Aug 20Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)
Aug 09Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified
Jul 05Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Nov 28Financial Position Analysis
Short Term Liabilities: MOREPENLAB's short term assets (₹10.9B) exceed its short term liabilities (₹4.1B).
Long Term Liabilities: MOREPENLAB's short term assets (₹10.9B) exceed its long term liabilities (₹453.2M).
Debt to Equity History and Analysis
Debt Level: MOREPENLAB has more cash than its total debt.
Reducing Debt: MOREPENLAB's debt to equity ratio has reduced from 64.2% to 3% over the past 5 years.
Debt Coverage: MOREPENLAB's debt is well covered by operating cash flow (144.2%).
Interest Coverage: MOREPENLAB's interest payments on its debt are well covered by EBIT (65.5x coverage).